MX2022000762A - Formulaciones orales de edaravone y metodo de fabricacion de las mismas. - Google Patents

Formulaciones orales de edaravone y metodo de fabricacion de las mismas.

Info

Publication number
MX2022000762A
MX2022000762A MX2022000762A MX2022000762A MX2022000762A MX 2022000762 A MX2022000762 A MX 2022000762A MX 2022000762 A MX2022000762 A MX 2022000762A MX 2022000762 A MX2022000762 A MX 2022000762A MX 2022000762 A MX2022000762 A MX 2022000762A
Authority
MX
Mexico
Prior art keywords
edaravone
dosage form
present
manufacturing
same
Prior art date
Application number
MX2022000762A
Other languages
English (en)
Spanish (es)
Inventor
Dharmesh Mahendrabhai Shah
Aravind Manappa Badiger
Bhavesh Naginbhai Patel
Rakshit Ketanbhai Choksi
Mayurkumar Purshottambhai Patil
Jigar Atulkumar Shah
Madhavkumar Dilipbhai Trivedi
Vishal Jayantilal Thakkar
Pratik Ashwinbhai Vora
Nirav Natvarlal Jadav
Original Assignee
Bdr Pharmaceuticals International Private Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bdr Pharmaceuticals International Private Ltd filed Critical Bdr Pharmaceuticals International Private Ltd
Publication of MX2022000762A publication Critical patent/MX2022000762A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2022000762A 2019-07-18 2020-07-17 Formulaciones orales de edaravone y metodo de fabricacion de las mismas. MX2022000762A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201921028874A IN201921028874A (cg-RX-API-DMAC7.html) 2019-07-18 2019-07-18
PCT/IN2020/050614 WO2021009775A1 (en) 2019-07-18 2020-07-17 Oral formulations of edaravone and method of manufacturing thereof

Publications (1)

Publication Number Publication Date
MX2022000762A true MX2022000762A (es) 2022-04-01

Family

ID=74210260

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022000762A MX2022000762A (es) 2019-07-18 2020-07-17 Formulaciones orales de edaravone y metodo de fabricacion de las mismas.

Country Status (9)

Country Link
US (1) US12691099B2 (cg-RX-API-DMAC7.html)
EP (1) EP3989968A4 (cg-RX-API-DMAC7.html)
BR (1) BR112022000914A2 (cg-RX-API-DMAC7.html)
CL (1) CL2022000118A1 (cg-RX-API-DMAC7.html)
IN (1) IN201921028874A (cg-RX-API-DMAC7.html)
MX (1) MX2022000762A (cg-RX-API-DMAC7.html)
PH (1) PH12022550117A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021009775A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202201541B (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112021008197A2 (pt) 2018-11-02 2021-08-03 Mitsubishi Tanabe Pharma Corporation suspensão de edaravone para administração oral
US11826352B2 (en) 2018-11-02 2023-11-28 Mitsubishi Tanabe Pharma Corporation Edaravone suspension for oral administration
JP2025530029A (ja) * 2022-08-18 2025-09-10 ビーディーアール ファーマシューティカルズ インターナショナル プライベート リミテッド エダラボンの経口製剤およびその改良された製造方法
WO2024172852A1 (en) 2023-02-16 2024-08-22 Slayback Pharma Llc Stable pharmaceutical compositions of edaravone
WO2026028170A1 (en) * 2024-08-02 2026-02-05 Lupin Limited Pharmaceutical composition of edaravone

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE473214C (de) 1925-10-22 1929-12-04 I G Farbenindustrie Akt Ges Verfahren zur Herstellung von 1-Phenyl-3-methyl-5-pyrazolon
ES2248144T3 (es) 2000-10-24 2006-03-16 Mitsubishi Pharma Corporation Medicamentos para tratar la esclerosis lateral amiotrofica (ela).
CN1440749A (zh) * 2003-03-24 2003-09-10 南昌弘益科技有限公司 易达拉封注射剂及其制备工艺——治疗急性脑梗塞
CN1241565C (zh) 2003-04-16 2006-02-15 浙江震元制药有限公司 依达拉奉药物组合物及制备
WO2009067343A1 (en) 2007-11-21 2009-05-28 Teikoku Pharma Usa, Inc. Pyrazolone derivative emulsion formulations
CN101953832B (zh) 2010-08-10 2012-02-15 南京师范大学 β-环糊精包合依达拉奉的口服药物组合物及其制备方法
CN102349893A (zh) * 2011-08-19 2012-02-15 福建天泉药业股份有限公司 依达拉奉药物组合物
CN105878171A (zh) * 2014-12-22 2016-08-24 南京海恒医药科技有限公司 一种依达拉奉新制剂及其制备方法
CN109125261B (zh) 2016-03-16 2021-11-30 苏州澳宗生物科技有限公司 依达拉奉剂型
CN107773545A (zh) * 2016-08-29 2018-03-09 烟台益诺依生物医药科技有限公司 依达拉奉与(+)‑2‑莰醇的舌下用药物组合物
EP3785703A1 (en) 2017-01-17 2021-03-03 Treeway TW001 B.V. Treatment comprising oral or gastric administration of edaravone
BR112019014712A2 (pt) 2017-01-17 2020-02-18 Treeway Tw001 B.V. Tratamento médio que compreende a administração entérica de edaravona
RU2693627C2 (ru) * 2017-11-03 2019-07-03 Общество С Ограниченной Ответственностью "Валента - Интеллект" Комбинации эдаравона для лечения ишемических повреждений мозга
WO2019213333A1 (en) * 2018-05-04 2019-11-07 Carnot2, Llc Combination therapies with edaravone and prodrugs of edaravone that are orally bioavailable and have altered pharmacokinetic properties
BR112021008197A2 (pt) * 2018-11-02 2021-08-03 Mitsubishi Tanabe Pharma Corporation suspensão de edaravone para administração oral

Also Published As

Publication number Publication date
US20220409588A1 (en) 2022-12-29
US12691099B2 (en) 2026-07-28
EP3989968A4 (en) 2023-07-12
ZA202201541B (en) 2023-05-31
PH12022550117A1 (en) 2022-12-19
CL2022000118A1 (es) 2023-03-10
EP3989968A1 (en) 2022-05-04
IN201921028874A (cg-RX-API-DMAC7.html) 2021-01-22
BR112022000914A2 (pt) 2022-03-08
WO2021009775A1 (en) 2021-01-21

Similar Documents

Publication Publication Date Title
PH12022550117A1 (en) Oral formulations of edaravone and method of manufacturing thereof
PH12017501321A1 (en) Oral care compositions and methods of use
CO2020013552A2 (es) Formulación de anticuerpos
MX2016017365A (es) Composicion que contiene minoxidil para el crecimiento del pelo.
BR112014009146A2 (pt) formulações de etanercepte estabilizadas com aminoácidos
EP4364802A3 (en) Compositions comprising methylphenidate-prodrugs, processes of making and using the same
EA202092829A1 (ru) Композиции тофацитиниба с контролируемым высвобождением
UY39390A (es) Forma amorfa de un inhibidor de la malt1 y formulaciones del mismo
MX2016011290A (es) Composiciones de ester de colina de acido lipoico y metodos de uso.
WO2015171460A3 (en) Formulations of cyclophosphamide liquid concentrate
WO2016125190A3 (en) Novel crystalline forms of vortioxetine, premixes, and processes for the preparation thereof
CO2020012963A2 (es) Composición farmacéutica y método de fabricación
EA201490363A1 (ru) Новые составы на основе (триметоксифениламино)пиримидинилов
UY34040A (es) Composiciones para disimular sabores y sus formas comestibles
CO2019014831A2 (es) Nuevas formulaciones orales de belinostat
PH12018501331A1 (en) Crystalline forms of thienopyrimidine compound
WO2018069805A3 (en) Method for preparation of liquid oral composition of l-thyroxin
PH12020500045A1 (en) Novel composition of enzalutamide oral dosage form and method of manufacturing thereof
WO2021006850A3 (en) Curcuminoid oral compositions comprising silica
CL2025000324A1 (es) Formulaciones orales de acetato de abiraterona y método de fabricación de las mismas.
MY196881A (en) Liquid composition for oral cavity
CU24718B1 (es) Nuevas formulaciones de comprimido de fosfomicina
AR025413A1 (es) Etil hex-5-enoato como un agente saborizante y metodos para preparar y usar el mismo
EA201692556A1 (ru) Стабилизированный десмопрессин
EA201691518A1 (ru) Композиции, содержащие продукты пчеловодства